Stay updated with breaking news from Head External. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Investegate announcements from Santhera Pharmaceuticals Holdi, Santhera to Announce 2020 Results on April 29, 2021
Pratteln, Switzerland, March 10, 2021 - Santhera Pharmaceuticals (SIX: SANN) announces that it has issued 480,708 treasury shares. The number of shares recorded in the commercial register has been increased
Santhera Pharmaceuticals Holding AG: Santhera Announces Results of Bondholders' Meeting Pratteln, Switzerland, March 9, 2021 - Santhera Pharmaceuticals (SIX: SANN) announces that while a large majority of 89 % of bondholders represented at yesterday's bondholders' meeting voted in favor of the resolutions proposed by the Company, the required threshold of 2/3 of all bonds outstanding to pass such resolutions was not met. Bondholders may still cast their vote for the resolution that would enable a restructuring of the CHF 60 million 5% Convertible Bonds due 2022. A total principal amount of C...
German NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. Pratteln, Switzerland, March 9, 2021 – Santhera Pharmaceuticals (SIX: SANN) announces that while a large majority of 89 % of bondholders represented at yesterday’s bondholders’ meeting voted in favor of the resolutions proposed by the Company, the required threshold of 2/3 of all bonds outstanding to pass such resolutions was not met. Bondholders may still cast their vote for the resolution that would enable a restructuring of the CHF 60 million ...
(2) Pratteln, Switzerland, March 3, 2021 - Santhera Pharmaceuticals (SIX: SANN) announces that the last patient has completed the last visit for the first period of the placebo-controlled pivotal VISION-DMD study with vamorolone in patients with Duchenne muscular dystrophy (DMD), conducted by partner ReveraGen Biopharma Inc. Subject to a positive 6-month topline data readout of this first study phase, this could allow for a regulatory submission to the US FDA in Q1-2022 with the potential to offer an alternative to current standard of care in DMD. The 48-week Phase 2b VISION-DMD study is des...